Bengaluru-based Kemwell Biopharma, a biologics contract development and manufacturing service provider, is working aggressively on augmenting its existing infrastructure. In addition, the CDMO is exploring strategic partnerships with biopharma players in the ecosystem to fit out its additional capacity which can be executed within 12-15 months.
The government plans to develop three mega bulk drug parks, which will be set up at a cost of Rs 14,300 Cr in association with various states to produce chemicals for life-saving drugs and reduce their imports from China.
The company has acquired an Ambr 250, added three single use bioreactors (SUBs) to support process scale-up, preclinical toxicology batch and early cGMP clinical trial supplies at 250L to 1000L scale in its current facility
Bengaluru based Kemwell Biopharma, a biologics contract development and manufacturing service provider, has recently augmented its existing infrastructure. As part of this expansion strategy, the company has installed Ambr® 250, a high throughput equipment with 12 fully automated mini bioreactors at a 250 ml scale to accelerate process development.
We are professional and reliable provider since we offer customers the most powerful and beautiful themes. Besides, we always catch the latest technology and adapt to follow world’s new trends to deliver the best themes to the market.
Read More ->